Weight-loss injections help shed kilos, but stopping them risks regaining the weight.

In recent years, medicines such as Mounjaro have sparked an intense wave of excitement. Multiple studies report striking improvements in body weight, blood glucose and cardiovascular risk factors. A major analysis of the active ingredient tirzepatide now raises an awkward question: is much of that success effectively wiped out as soon as the medication is stopped?

What tirzepatide does in the body – and why the weight drops so quickly

Tirzepatide is part of a newer generation of medicines that emerged from diabetes care. It binds to receptors for two gut hormones (GIP and GLP‑1) that influence hunger, fullness and blood glucose regulation. Put simply: appetite tends to fall sharply, the body handles energy more sparingly, and the pancreas can work more steadily.

In the large SURMOUNT‑4 trial, adults with obesity or severe overweight used the treatment for 36 weeks. Alongside this, they received dietary guidance and followed a structured exercise programme. The results included:

• an average loss of around 20% of body weight
• improved blood glucose readings
• healthier blood lipids, including lower “bad” LDL cholesterol
• reduced blood pressure

For many people, a loss of this magnitude is not only about smaller clothes sizes; it can also mean a substantially lower risk of heart attack, stroke and diabetes.

For many specialists, this positioned tirzepatide as a potential turning point in obesity treatment. But the real test still remained: what happens once the injections stop?

The second phase of the SURMOUNT‑4 trial: stopping versus continuing tirzepatide

After the first phase, the researchers split participants into two groups. One group continued receiving tirzepatide; the other switched to an inactive placebo. Neither group knew who was receiving which treatment. This double‑blind design helps prevent expectations from skewing results.

The key question was straightforward: does the benefit persist when the medication ends, or does the body drift back towards its starting point?

Rapid weight loss, then rapid weight regain after stopping tirzepatide

The findings were sobering. In the placebo group, a clear pattern emerged: most people regained a noticeable amount of weight.

• 82% regained at least a quarter of the weight they had previously lost.
• Some individuals regained three quarters of the lost kilograms.
• This happened within roughly a year after treatment ended.

As weight returned, many risk markers moved in the wrong direction again: LDL cholesterol rose, blood pressure crept up, and blood glucose control deteriorated. Among those who regained more weight, several measurements ended up close to baseline-almost as though the 20% weight loss had never happened.

The more weight participants regained after stopping, the more strongly their metabolic markers worsened-a direct, measurable reversal.

To experts, this aligns with what has long been observed in obesity: excess weight pushes blood glucose, blood pressure and blood lipids upwards. Lose weight and markers improve; regain it and risks rise again.

Obesity as a chronic disease: is one injection ever enough?

These results place the current enthusiasm around weight‑loss injections into a more realistic frame. Obesity is widely recognised as a chronic condition, comparable in many ways to high blood pressure or diabetes. For illnesses like these, few would argue that treatment should automatically become unnecessary after only a few months.

Professional bodies are therefore increasingly discussing whether medicines such as tirzepatide should be viewed as long‑term therapy. That brings several implications:

• Patients would need long‑term dose optimisation and follow‑up.
• Health systems could face substantial costs over many years.
• Clinicians would need to be more selective about who is most likely to benefit.

At the same time, psychologists such as Jane Ogden warn that some people change their day‑to‑day habits very little during treatment. When hunger is suppressed pharmacologically, individuals may cook less, stop planning meals and rely heavily on the medication. If that “pharmacological shield” is removed, any structure that was never built can disappear too.

Without lasting changes to everyday routines, the medication can become a crutch-remove it, and the body stumbles back into old patterns.

Why stopping tirzepatide without a plan is so risky

The study highlights not only a medical challenge but also a practical one. Several experts are calling for a clear strategy for the period after any potential stopping of treatment. Suggested elements include:

• frequent weight monitoring
• tailored nutrition programmes
• supervised physical activity, such as community rehabilitation exercise schemes or cardiac exercise groups
• psychological support when eating is strongly shaped by emotions

The first months after discontinuation are often seen as a high‑risk window. Without structured support, it is easy to slide into a yo‑yo effect, with familiar consequences for cardiovascular and metabolic health.

Financial and ethical questions around long‑term tirzepatide use

Long‑term use of these medicines is expensive. Commissioners and hospitals will have to weigh difficult trade‑offs: how many heart attacks, strokes and cases of dialysis might be prevented in the long run? How does mortality change if high‑risk patients can maintain meaningful weight reduction over years? Only longer observation periods will clarify whether widespread use is cost‑effective.

Ethical issues also come into play. Should a very costly medicine be used indefinitely for people whose concern is primarily cosmetic and who do not yet carry a high medical risk? Or should access be prioritised for those already facing serious complications?

Special situations: fertility plans, pregnancy, and vulnerable groups

The researchers also point to signals from other studies: if women stop the medication shortly before pregnancy, there may be a higher risk of gestational diabetes and certain birth complications. Evidence remains limited, but many clinicians now advise incorporating pregnancy intentions early into treatment planning.

For very young or very old patients, questions about long‑term tolerability become even more important. People with existing conditions affecting the stomach, bowel or pancreas are also among those for whom clinicians tend to apply extra caution.

What people can learn from the latest tirzepatide data

Anyone considering tirzepatide or similar treatments should read these findings not as a warning against the medicine itself, but as a warning against unrealistic expectations. The effect can be powerful-yet it appears closely tied to continued treatment.

A practical plan might look like this:

• Begin treatment in a specialist clinic or practice.
• Build new routines in parallel: regular meal times, more movement, and stress reduction.
• Monitor blood pressure, blood glucose and blood lipids at regular intervals.
• Only after sustained behavioural change, consider a careful dose reduction-if it is appropriate at all.

Using the medication as a “quick fix” and then returning to previous habits risks the same trap seen with crash diets: weight tends to return-often more quickly than expected-and metabolic health can suffer twice over.

Building sustainable success with tirzepatide: combining medication with lifestyle support

Over time, a blended approach is likely to become standard: medicines such as tirzepatide used as a powerful tool, embedded within a closely supported programme covering nutrition, physical activity and psychological care. This kind of structure improves the odds that it is not only the scales that benefit, but also the heart and blood vessels-lasting well beyond the early phase of treatment.

Planning for maintenance: preventing weight regain after tirzepatide

Because weight regain can occur rapidly, maintenance should be treated as its own phase of care. That can include setting a target “maintenance range” rather than a single number, arranging follow‑ups before the final dose is given, and agreeing in advance what steps will be taken if weight begins to rise-so decisions are proactive, not reactive.